Clay Siegall is a co-founder of Seattle Genetics where he serves as the Board Chairman, President and CEO. He co-founded the company with his partner in 1998. A trained scientist, Clay Siegall attended the George Washington University where studied genetics and the University of Maryland where he studied Zoology. Clay recently held an interview session with Ideamensch where he discussed his involvement with Seattle Genetics. According to him, decided to start the company after watching his father suffer from cancer when he was a small boy. Clay then decided to improve the small resources and tools that are used in treating cancer by oncologists and other specialists.
On the question of what makes him to be more productive, Clay Siegall said that he reminds himself constantly he does not know all the things and that he is the process of learning. He stated that he is a great team worker and he likes to interact with people who are smart so as to gain more information. According to Clay Siegall, having an open mind is an important aspect when it comes to business success. An established author, Clay Siegall has over the years co-authored and authored more than 70 publications on medicine and science.
Clay Siegall works with other medical institutions such as Ultragenyx Pharmaceutical, Washington Roundtable, and also Alder BioPharmaceuticals. A non-profit organization, the Washington Roundtable involves CEOs coming from the biggest employers in the Washington State. Clay got the Maryland Alumnus of the Year for Computer, Math and Natural Sciences because of his contributions to biotechnology pioneering and cancer research. Because of the growth of Seattle Genetics, Clay Siegall received the distinction of the Pacific Northwest Ernst & Young Entrepreneur of the Year. Dr. Siegall has an experience of over 20 years in both cancer research and therapeutic drug development.
Clay Siegall was once a Senior Research Investigator with the Bristol-Myers Squibb Pharmaceutical research Institute. He is the Director at WBBA (Washington Biotechnology and Biomedical Association). At Mirna Therapeutics, Inc, Clay Siegall serves as anon Executive Director. He works in the Board of Editors at 3 scientific journals and also is in the Board at the Scientific Counselors for the Cancer Treatment Research Foundation.